To improve cancer patient outcomes by developing
advanced oncology diagnostics.
Circulating Tumor Cells are robust biomarkers that may help oncologists make more informed cancer treatment decisions. Currently available CTC capture technologies may not be sensitive enough to realize the full potential of CTCs. Early data using our CapioCyte technology with clinical samples has shown very promising results
An innovative and ultra-sensitive technology for the capture and analysis of CTCs from whole blood
Our clinical data show a sensitivity of up to
10 to 100 times greater
than previously published data using other currently available platforms.
This enhanced sensitivity makes the CapioCyte platform an excellent tool for cancer research,
and potential clinical use in the future.